bioAffinity Technologies Inc

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports fourth quarter and full year 2023 financial results.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share.

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NASDAQ: BIAF; BIAFW) has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.5625 per common share.

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sandeep Bansal, M.D., joins bioAffinity Medical and Science Advisory Board; adds CyPath Lung to his practice.

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.

bioAffinity Technologies In The News

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.

bioAffinity Technologies In the News

BioVie Inc

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET).

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024

SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the appointment of Dallas Coleman as National Director of Sales.

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.

bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The laboratory asse.

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AMA--The AMA has issued a CPT code specifically for bioAffinity Technologies' CyPath® Lung noninvasive test for early-stage lung cancer.

AMA Issues CPT Code for bioAffinity Technologies' CyPath® Lung Test for Early-Stage Lung Cancer

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research at UMass 5th annual RNA Therapeutics Symposium June 21-23.

bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research findings at CYTO 2023.

bioAffinity Technologies Presents Research Findings at CYTO 2023

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases first quarter 2023 financial results and reports progress on CyPath Lung diagnostic.

News for bioAffinity Technologies Inc Stock (BIAF)